Novo Nordisk is Rated Supersector Leader in the 2007 Dow Jones Sustainability Indexes
- Details
- Category: Novo Nordisk
![Novo Nordisk Novo Nordisk](http://www.worldpharmanews.com/images/stories/logo/novonordisk_b.gif)
Dow Jones Sustainability Index Again Recognizes Abbott
- Details
- Category: Abbott
![Abbott Abbott](http://www.worldpharmanews.com/images/stories/logo/abbott.gif)
Avastin approved in Europe for first-line treatment of patients with advanced lung cancer
- Details
- Category: Roche
![Roche Roche](http://www.worldpharmanews.com/images/stories/logo/roche.gif)
CeNeS and ERGOMED Report Start of Recruitment for Phase II trial of CNS 5161 in cancer pain
- Details
- Category: Clinical Trials
CeNeS Pharmaceuticals plc (AIM: CEN) and the ERGOMED Group today announced that they have initiated recruitment into a Phase II study of the potential new pain drug CNS 5161. CNS 5161 is being developed under a co-development deal signed in July 2006 between CeNeS and ERGOMED.
AstraZeneca and Pozen To Start Phase III Trials With PN400
- Details
- Category: AstraZeneca
![AstraZeneca AstraZeneca](http://www.worldpharmanews.com/images/stories/logo/astrazeneca_b.gif)
Bayer intends to delist from the New York Stock Exchange
- Details
- Category: Bayer
![Bayer AG Bayer AG](http://www.worldpharmanews.com/images/stories/logo/bayer.gif)
Novartis to defend its intellectual property rights for Famvir®
- Details
- Category: Novartis
![Novartis AG Novartis AG](http://www.worldpharmanews.com/images/stories/logo/novartis_b.gif)
More Pharma News ...
- Boehringer Ingelheim announce major global strategic alliance in novel nanobody® therapeutics
- Novartis completes divestment program with transfer of Gerber baby foods business
- GlaxoSmithKline receives approval for Atriance® (nelarabine) in Europe
- RotaTeq® Proves to Maintain High Clinical Efficacy Two Years Post-Vaccination in Europe
- Pfizer Launches Five Year, Three Country Initiative for Malaria Treatment and Education
- Study Shows IRESSA (Gefitinib) Is As Effective As Docetaxel In Pre-Treated Advanced NSCLC
- Significant 30 Percent Increase in Relative Risk of Cardiovascular Events or Death